Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Efficacy, safety, and cost of new anticancer drugs.

Literature DB >> 12153927

Efficacy, safety, and cost of new anticancer drugs.

Silvio Garattini¹, Vittorio Bertele.

Abstract

Mesh：

Substances：
Antineoplastic Agents

Year: 2002 PMID： 12153927 PMCID： PMC1123779 DOI： 10.1136/bmj.325.7358.269

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

12 in total

1. Temozolomide for malignant brain tumours.

Authors: T Batchelor
Journal: Lancet Date: 2000-04-01 Impact factor: 79.321

2. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors: M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal: JAMA Date: 1999-10-20 Impact factor: 56.272

3. Adjusting Europe's drug regulation to public health needs.

Authors: S Garattini; V Bertele
Journal: Lancet Date: 2001-07-07 Impact factor: 79.321

4. The decline in cancer mortality in the European Union, 1988-1996.

Authors: F Levi; F Lucchini; E Negri; C La Vecchia
Journal: Eur J Cancer Date: 2000-10 Impact factor: 9.162

Review 5. Antibody-targeted immunotherapy for treatment of malignancy.

Authors: C A White; R L Weaver; A J Grillo-López
Journal: Annu Rev Med Date: 2001 Impact factor: 13.739

6. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.

Authors: B P Findlay; C Walker-Dilks
Journal: Cancer Prev Control Date: 1998-06

7. Cancer undefeated.

Authors: J C Bailar; H L Gornik
Journal: N Engl J Med Date: 1997-05-29 Impact factor: 91.245

8. Introduction: the EUROCARE II Study.

Authors: F Berrino; G Gatta; E Chessa; F Valente; R Capocaccia
Journal: Eur J Cancer Date: 1998-12 Impact factor: 9.162

9. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors:
Journal: Lancet Date: 1998-09-19 Impact factor: 79.321

10. Opinion: why the variation in breast cancer survival in Europe?

Authors: M P Coleman
Journal: Breast Cancer Res Date: 1999-10-07 Impact factor: 6.466

27 in total

1. Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.

Authors: Hilary Calvert; Duncan I Jodrell; James Cassidy; Adrian L Harris
Journal: BMJ Date: 2002-11-30

Review 2. Education and debate: Making regulation responsive to commercial interests: streamlining drug industry watchdogs.

Authors: John Abraham; Danielle Bardelay; Christophe Kopp; J D Kleinke; Emma Bennion
Journal: BMJ Date: 2002-11-16

Efficacy, safety, and cost of new anticancer drugs.

1. Temozolomide for malignant brain tumours.

2. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

3. Adjusting Europe's drug regulation to public health needs.

4. The decline in cancer mortality in the European Union, 1988-1996.

Review 5. Antibody-targeted immunotherapy for treatment of malignancy.

6. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.

7. Cancer undefeated.

8. Introduction: the EUROCARE II Study.

9. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

10. Opinion: why the variation in breast cancer survival in Europe?

1. Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.

Review 2. Education and debate: Making regulation responsive to commercial interests: streamlining drug industry watchdogs.

3. Efficacy, safety and cost of new drugs acting on the central nervous system.

4. Efficacy, safety and cost of new cardiovascular drugs: a survey.

5. Challenges for the National Institute for Clinical Excellence.

6. EMA's reflection on placebo does not reflect patients' interests.

7. Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.

Review 8. Risk:benefit assessment of old medicines.

9. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003.

10. An update on the first decade of the European centralized procedure: how many innovative drugs?